Tki sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant alk+ tumors

Amit Dipak Amin, Lingxiao Li, Soumya S. Rajan, Vijay Gokhale, Matthew J. Groysman, Praechompoo Pongtornpipat, Edgar O. Tapia, Mengdie Wang, Jonathan H Schatz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The anaplastic lymphoma kinase (ALK) protein drives tumorigenesis in subsets of several tumors through chromosomal rearrangements that express and activate its C-terminal kinase domain. In addition, germline predisposition alleles and acquired mutations are found in the full-length protein in the pediatric tumor neuroblastoma.ALK-specific tyrosine kinase inhibitors (TKIs) have become important new drugs for ALK-driven lung cancer, but acquired resistance via multiple mechanisms including kinase-domain mutations eventually develops, limiting median progression-free survival to less than a year. Here we assess the impact of several kinase-domain mutations thatarose during TKI resistance selections of ALK+ anaplastic large-cell lymphoma (ALCL)cell lines. These include novel variants with respect to ALK-fusion cancers, R1192P and T1151M, and with respect to ALCL, F1174L and I1171S. We assess the effects of these mutations on the activity of six clinical inhibitors in independent systems engineeredto depend on either the ALCL fusion kinase NPM-ALK or the lung-cancer fusion kinase EML4-ALK. Our results inform treatment strategies with a likelihood of by passing mutations when detected in resistant patient samples and highlight differences betweenthe effects of particular mutations on the two ALK fusions.

Original languageEnglish (US)
Pages (from-to)23715-23729
Number of pages15
JournalOncotarget
Volume7
Issue number17
DOIs
StatePublished - Apr 26 2016

Fingerprint

Phosphotransferases
Mutation
Anaplastic Large-Cell Lymphoma
Neoplasms
Therapeutics
Protein-Tyrosine Kinases
Lung Neoplasms
anaplastic lymphoma kinase
Cell Fusion
Neuroblastoma
Disease-Free Survival
Carcinogenesis
Proteins
Alleles
Pediatrics
Cell Line
Pharmaceutical Preparations

Keywords

  • Alectinib
  • Anaplastic lymphoma kinase
  • Ceritinib
  • Crizotinib
  • Drug resistance

ASJC Scopus subject areas

  • Oncology

Cite this

Tki sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant alk+ tumors. / Amin, Amit Dipak; Li, Lingxiao; Rajan, Soumya S.; Gokhale, Vijay; Groysman, Matthew J.; Pongtornpipat, Praechompoo; Tapia, Edgar O.; Wang, Mengdie; Schatz, Jonathan H.

In: Oncotarget, Vol. 7, No. 17, 26.04.2016, p. 23715-23729.

Research output: Contribution to journalArticle

Amin, AD, Li, L, Rajan, SS, Gokhale, V, Groysman, MJ, Pongtornpipat, P, Tapia, EO, Wang, M & Schatz, JH 2016, 'Tki sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant alk+ tumors', Oncotarget, vol. 7, no. 17, pp. 23715-23729. https://doi.org/10.18632/oncotarget.8173
Amin, Amit Dipak ; Li, Lingxiao ; Rajan, Soumya S. ; Gokhale, Vijay ; Groysman, Matthew J. ; Pongtornpipat, Praechompoo ; Tapia, Edgar O. ; Wang, Mengdie ; Schatz, Jonathan H. / Tki sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant alk+ tumors. In: Oncotarget. 2016 ; Vol. 7, No. 17. pp. 23715-23729.
@article{2a3a8c3112da46a3807e46d1af562bdd,
title = "Tki sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant alk+ tumors",
abstract = "The anaplastic lymphoma kinase (ALK) protein drives tumorigenesis in subsets of several tumors through chromosomal rearrangements that express and activate its C-terminal kinase domain. In addition, germline predisposition alleles and acquired mutations are found in the full-length protein in the pediatric tumor neuroblastoma.ALK-specific tyrosine kinase inhibitors (TKIs) have become important new drugs for ALK-driven lung cancer, but acquired resistance via multiple mechanisms including kinase-domain mutations eventually develops, limiting median progression-free survival to less than a year. Here we assess the impact of several kinase-domain mutations thatarose during TKI resistance selections of ALK+ anaplastic large-cell lymphoma (ALCL)cell lines. These include novel variants with respect to ALK-fusion cancers, R1192P and T1151M, and with respect to ALCL, F1174L and I1171S. We assess the effects of these mutations on the activity of six clinical inhibitors in independent systems engineeredto depend on either the ALCL fusion kinase NPM-ALK or the lung-cancer fusion kinase EML4-ALK. Our results inform treatment strategies with a likelihood of by passing mutations when detected in resistant patient samples and highlight differences betweenthe effects of particular mutations on the two ALK fusions.",
keywords = "Alectinib, Anaplastic lymphoma kinase, Ceritinib, Crizotinib, Drug resistance",
author = "Amin, {Amit Dipak} and Lingxiao Li and Rajan, {Soumya S.} and Vijay Gokhale and Groysman, {Matthew J.} and Praechompoo Pongtornpipat and Tapia, {Edgar O.} and Mengdie Wang and Schatz, {Jonathan H}",
year = "2016",
month = "4",
day = "26",
doi = "10.18632/oncotarget.8173",
language = "English (US)",
volume = "7",
pages = "23715--23729",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "17",

}

TY - JOUR

T1 - Tki sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant alk+ tumors

AU - Amin, Amit Dipak

AU - Li, Lingxiao

AU - Rajan, Soumya S.

AU - Gokhale, Vijay

AU - Groysman, Matthew J.

AU - Pongtornpipat, Praechompoo

AU - Tapia, Edgar O.

AU - Wang, Mengdie

AU - Schatz, Jonathan H

PY - 2016/4/26

Y1 - 2016/4/26

N2 - The anaplastic lymphoma kinase (ALK) protein drives tumorigenesis in subsets of several tumors through chromosomal rearrangements that express and activate its C-terminal kinase domain. In addition, germline predisposition alleles and acquired mutations are found in the full-length protein in the pediatric tumor neuroblastoma.ALK-specific tyrosine kinase inhibitors (TKIs) have become important new drugs for ALK-driven lung cancer, but acquired resistance via multiple mechanisms including kinase-domain mutations eventually develops, limiting median progression-free survival to less than a year. Here we assess the impact of several kinase-domain mutations thatarose during TKI resistance selections of ALK+ anaplastic large-cell lymphoma (ALCL)cell lines. These include novel variants with respect to ALK-fusion cancers, R1192P and T1151M, and with respect to ALCL, F1174L and I1171S. We assess the effects of these mutations on the activity of six clinical inhibitors in independent systems engineeredto depend on either the ALCL fusion kinase NPM-ALK or the lung-cancer fusion kinase EML4-ALK. Our results inform treatment strategies with a likelihood of by passing mutations when detected in resistant patient samples and highlight differences betweenthe effects of particular mutations on the two ALK fusions.

AB - The anaplastic lymphoma kinase (ALK) protein drives tumorigenesis in subsets of several tumors through chromosomal rearrangements that express and activate its C-terminal kinase domain. In addition, germline predisposition alleles and acquired mutations are found in the full-length protein in the pediatric tumor neuroblastoma.ALK-specific tyrosine kinase inhibitors (TKIs) have become important new drugs for ALK-driven lung cancer, but acquired resistance via multiple mechanisms including kinase-domain mutations eventually develops, limiting median progression-free survival to less than a year. Here we assess the impact of several kinase-domain mutations thatarose during TKI resistance selections of ALK+ anaplastic large-cell lymphoma (ALCL)cell lines. These include novel variants with respect to ALK-fusion cancers, R1192P and T1151M, and with respect to ALCL, F1174L and I1171S. We assess the effects of these mutations on the activity of six clinical inhibitors in independent systems engineeredto depend on either the ALCL fusion kinase NPM-ALK or the lung-cancer fusion kinase EML4-ALK. Our results inform treatment strategies with a likelihood of by passing mutations when detected in resistant patient samples and highlight differences betweenthe effects of particular mutations on the two ALK fusions.

KW - Alectinib

KW - Anaplastic lymphoma kinase

KW - Ceritinib

KW - Crizotinib

KW - Drug resistance

UR - http://www.scopus.com/inward/record.url?scp=84966589415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966589415&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8173

DO - 10.18632/oncotarget.8173

M3 - Article

C2 - 27009859

AN - SCOPUS:84966589415

VL - 7

SP - 23715

EP - 23729

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 17

ER -